De Sourav, Kumar S K Ashok, Shah Suraj Kumar, Kazi Sabnaz, Sarkar Nandan, Banerjee Subhasis, Dey Sanjay
Department of Pharmaceutical Technology, School of Medical Science, Adamas University Kolkata-700126 West Bengal India
Department of Chemistry, School of Advanced Sciences, VIT Vellore-632014 India
RSC Adv. 2022 May 20;12(24):15385-15406. doi: 10.1039/d2ra01571d. eCollection 2022 May 17.
The nitrogen-bearing heterocycle pyridine in its several analogous forms occupies an important position as a precious source of clinically useful agents in the field of medicinal chemistry research. This privileged scaffold has been consistently incorporated in a diverse range of drug candidates approved by the FDA (Food and Drug Administration). This moiety has attracted increasing attention from several disease states owing to its ease of parallelization and testing potential pertaining to the chemical space. In the next few years, a larger share of novel pyridine-based drug candidates is expected. This review unifies the current advances in novel pyridine-based molecular frameworks and their unique clinical relevance as reported over the last two decades. It highlights an inclination to the use of pyridine-based molecules in drug crafting and the subsequent emergence of several potent and eligible candidates against a range of diversified diseases.
含氮杂环吡啶及其几种类似形式,在药物化学研究领域作为临床有用药物的宝贵来源占据重要地位。这种特权骨架一直被纳入美国食品药品监督管理局(FDA)批准的各种候选药物中。由于其易于平行化以及与化学空间相关的测试潜力,该部分已引起多种疾病状态研究的越来越多关注。在未来几年,预计新型吡啶类候选药物的占比会更大。本综述总结了过去二十年来报道的新型吡啶类分子框架的当前进展及其独特的临床相关性。它强调了在药物研发中使用吡啶类分子的趋势,以及随后出现的针对多种不同疾病的几种有效且合格的候选药物。